Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Soligenix News

    0,383 $ 0,00% +0,00 $
    In : 0,3577 € | 24.04.24 22:00:00 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3D506
    ISIN: US8342235053
    US-Symbol: SNGX
    Typ: Aktie

    Soligenix News

    18.04.24 - PR Newswire
    Soligenix Announces Pricing of $4.75 Million Public Offering
    Soligenix Announces Pricing of $4.75 Million Public Offering PR Newswire
    15.04.24 - PR Newswire
    FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
    FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-​Exposure Prophylaxis Against Marburg Marburgvirus Infection PR Newswire
    11.04.24 - PR Newswire
    FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
    FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-​Exposure Prophylaxis Against Sudan Ebolavirus Infection PR Newswire
    03.04.24 - PR Newswire
    Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
    Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-​Controlled Trial for HyBryte™ With the European Medicines Agency PR Newswire
    15.03.24 - PR Newswire
    Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
    Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results PR Newswire
    08.02.24 - PR Newswire
    Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
    Soligenix Announces Formation of Behçet's Disease Medical Advisory Board PR Newswire
    25.01.24 - PR Newswire
    Soligenix to Present at The Microcap Conference
    Soligenix to Present at The Microcap Conference PR Newswire
    08.01.24 - PR Newswire
    FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
    FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease PR Newswire
    04.01.24 - PR Newswire
    Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
    Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-​to-Moderate Psoriasis PR Newswire
    02.01.24 - PR Newswire
    Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
    Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses PR Newswire
    01.12.23 - PR Newswire
    "HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery
    "HyBryte™ Use in Early-​Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery PR Newswire
    30.11.23 - PR Newswire
    Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
    Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease PR Newswire
    17.11.23 - PR Newswire
    Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
    Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting PR Newswire
    13.11.23 - PR Newswire
    Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results
    Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results PR Newswire
    20.10.23 - PR Newswire
    Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
    Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting PR Newswire
    16.10.23 - PR Newswire
    Soligenix to Present at The ThinkEquity Conference
    Soligenix to Present at The ThinkEquity Conference PR Newswire
    25.09.23 - PR Newswire
    Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures
    Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures PR Newswire
    22.09.23 - PR Newswire
    Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders
    Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders PR Newswire
    21.08.23 - PR Newswire
    Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results
    Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results PR Newswire
    10.08.23 - PR Newswire
    HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
    HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment PR Newswire

    Newssuche

    Videos

    newspaper
    24.04.24
    Technical Trading: AUD/USD mit Mega Chance
    AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »